You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Cells
Download PDF
  • Review
  • Open Access

7 August 2023

What’s in a Name? An Overview of the Proliferating Nomenclature in the Field of Phage Lysins

and
Laboratory of Applied Biotechnology, Department of Biotechnology, Ghent University, 9000 Ghent, Belgium
*
Authors to whom correspondence should be addressed.
Cells2023, 12(15), 2016;https://doi.org/10.3390/cells12152016
This article belongs to the Special Issue Bacteriophages and Their Enzymes as Antibacterial Agents
Version Notes
Order Reprints
Review Reports

Abstract

In the last few years, the volume of research produced on phage lysins has grown spectacularly due to the interest in using them as alternative antimicrobials. As a result, a plethora of naming customs has sprouted among the different research groups devoted to them. While the naming diversity accounts for the vitality of the topic, on too many occasions it also creates some confusion and lack of comparability between different works. This article aims at clarifying the ambiguities found among names referring to phage lysins. We do so by tackling the naming customs historically, framing their original adoption, and employing a semantic classification to facilitate their discussion. We propose a periodization of phage lysin research that begins at the discovery era, in the early 20th century, enriches with a strong molecular biology period, and grows into a current time of markedly applied research. During these different periods, names referring to the general concepts surrounding lysins have been created and adopted, as well as other more specific terms related to their structure and function or, finally, names that have been coined for the antimicrobial application and engineering of phage lysins. Thus, this article means to serve as an invitation to the global lysin community to take action and discuss a widely supported, standardized nomenclature.

1. Introduction

Research on “phage lysins” is a hot topic these days: in this so-called “post-antibiotic” world to come, the questions and answers on how to handle antibiotic-resistant bacteria are one of the most apparent drivers for innovation in antimicrobial discovery. Under the influence of this contemporary challenge, bacteriophage research has drifted towards an eminently applied focus of breadth and intensity unheard of (in the West) since the early days of phage. That is how we end up today with a globally growing community of researchers putting their efforts not only on the development of full virion phage therapy [1,2] but also on repurposing phage enzymatic products as antibacterial drugs [3,4,5]. This latter approach has quickly gained relevance since some seminal papers published in the early 2000s by the V. Fischetti group at Rockefeller University [6,7,8]—although the general idea of using enzymes as therapeutic agents was already present in much earlier literature [9,10]. The interest in these enzymatic phage products —which are usually referred to as “lysins”—has spectacularly grown in the last few years, probably due to two factors: (1) the purely scientific interest sparked by the versatility and amenability of this kind of proteins for engineering, biochemical, functional or evolutionary studies [11,12,13,14], as well as by the massive amount of (sequence) data and prior knowledge publicly available [15,16,17] and (2) the feasibility of lysins as a new kind of antibacterial that can fit within the regulatory, industrial, and clinical frameworks and pipelines already established for the production of therapeutic proteins (biologicals) [18]. In this perspective, it is relevant to note that, according to the current literature, it can be said that phage lysins fulfill the four innovation criteria defined by the World Health Organization: being a new class of antibiotics, having a new mode of action, a new target, and lack of known cross-resistance [19].
All of these new research efforts come with their own nomenclature innovations as much as they have continued the naming traditions of the field, with diverse emphases and novel uses. Therefore, we stand at a point where names in the phage lysin field proliferate and are sometimes used too flexibly, which, in turn, creates a sometimes -ambiguous research ecosystem, which is difficult to penetrate for the lysin-layman and exhausting to navigate for experts. Indeed, the naming proliferation reflects the vitality of the phage lysin field. However, it also faces us with what can become an uncontrollable Tower of Babel, in which retrieving and comparing data from all the international stakeholder groups becomes increasingly complicated. This article thus intends to establish the basis for an ordered discussion on the naming customs in the phage lysin field.
If we are to discuss “customs”, the appropriate way to do so is by relying on the historical circumstances that explain them. At least three “eras” can be clearly described in the history of lysin nomenclature, and each of them encompasses a set of names and concepts devised within it (Figure 1).
Figure 1. Conceptual outline for the discussion of nomenclature in the phage lysins field.
(1)
Discovery era: roughly between the early 20th century and the 1940s, the fundamental terminology in the field was developed at the same time that phenomena were first time described.
(2)
Molecular era: in the central and final years of the 20th century, phage research entered the molecular biology era in which the infection and enzyme activity mechanisms were elucidated.
(3)
Applied era: since the beginning of the 21st century, phage lysin research entered a more markedly applied stage driven by the antibiotic resistance crisis. At this point, more distinctions came into place, many of which are related to the new role of lysins as antimicrobials. Even more remarkable is the plethora of common names given to the vast number of new lysins being described and investigated, both wild type and engineered, following the most diverse reasonings.
In this work, lysin-related names will be thematically reviewed, attending to their different semantic levels: (1) general terminology for lysins, (2) terms related to the structure and function of lysins, (3) names for lysins as antibacterial agents and (4) nomenclature of individual lysins. For each case, the appropriate historical background will also be provided, considering the periodization established above (Figure 1).

2. General Terminology for Lysins

According to our PubMed-based survey (Table 1), the terms “lysin” or “endolysin” are the most popular names given to these enzymes encoded in phage genomes whose main function is to actively and directly cause bacterial host cell lysis at the end of the replication cycle. “Lysin” is indeed a rather old name, which can be traced back, in the phage context, to the days of Felix d’Herelle [20] (see Supplementary Materials for an English translation of the earliest example of the use of the term “lysin” applied to a suspected enzyme accompanying the “bacteriophage phenomenon”) and Frederick Twort’s [21] pioneering research. However, given the still unclear identity and molecular basis for the “bacteriophage phenomenon” at the time, the term “lysin” was still confusedly applied in general to observations of “clearance” in the field of immunology, bacteriology or the incipient virology. This eminently occurs in the early articles by Twort (see e.g., [21]), in which he refers to the bacteriophage (still hesitantly identified by him as an “ultramicroscopic virus”) rather indistinctly as “lysin”. Even in a later stage, when the identity of the phage as a replicating virus was more or less clear and the original distinction posed by d’Herelle between a non-transmissible lysin and a transmissible virus was somewhat adopted, “lysin” was still confusedly used for observations linked both with the peptidoglycan degradation activity—the proper cell lysis—and the action of phage depolymerases [22]. When it was made clear that the action of depolymerases was separate from the key role of lysins in the phage infective cycle, the name “lysins” mostly acquired the meaning of “peptidoglycan-degrading enzyme”. From then on, any other non-enzymatic player in host lysis (holins, pinholins, spanins, or releasins) was left out of the “lysin” class (although these proteins were only discovered later [23,24,25]). Thus, lysins are also referred to as peptidoglycan-degrading enzymes or their pure synonym, “muralytic enzymes”. Taking these distinctions into account, “phage lytic enzyme” can function as a synonym of lysin, but “phage lytic protein” is ambiguous since the non-enzymatic agents of phage-mediated lysis can easily be included under this name.
Table 1. Number of references found by PubMed searches regarding relevant phage lysin-related terms. a As found in the indicated PubMed searches (performed on 26 May 2023) including, when available, article titles, abstract, whole text and/or MeSH terms.
Of note, phage depolymerases (more accurately “exopolysaccharide—EPS—depolymerases” and also anecdotally known as “biofilm-disrupting enzymes”) have also been considered as “phage lytic enzymes” [26], although this may also be a remnant of the times when some confusion still existed between the actual lawn clearance of plaques and depolymerase-induced halos.
The similar but more meaningful term “endolysin” seems now to be preferred to the simpler “lysin” (Table 1). This name dates back to the mid-20th century [27,28,29,30] as applied to phage lysins (it was earlier—although fleetingly—used to designate a bacteriolytic substance “present in extracts of leukocytes” [19]). Of no surprise, this is also the time in which the specific role of the endolysin as an unequivocally enzymatic player, key to the release of the phage progeny—or lysis “from within”—was elucidated. Despite the somewhat “liberal” current use to designate lysis-exerting, peptidoglycan-degrading, phage-encoded enzymes, the strict etymological sense of “endolysin” raises a problem. Given its Greek meaning (“lysis from within”), it should be preferentially reserved to the lysis-inducing enzyme that is produced within the host and released towards the cell wall at the end of the phage lytic cycle. Nonetheless, it is now (misleadingly?) used to refer both to the native endolysins found at the lytic cassette of phage genomes as much as to synthetic or engineered lysins that cannot be longer identified as an enzyme with such a physiological function. On the other hand, the preference towards “endolysin” may be explained because the name “lysin” can be equivocal, especially in the context of automatic database searches or in communicating science to the laymen (i.e., it is too similar to the amino acid “lysine”). The phrase “phage lysin”, however, preserves the meaning (lytic enzyme from phage origin) while avoiding misunderstandings and the misnaming of any peptidoglycan-degrading enzyme from phage origin as an endolysin.
This is important because phages do not only encode lysins at their lytic cassette, i.e., not all phage lysins are, in fact, endolysins. Since the mid-20th century, a muralytic activity was known to be present within the viral particles of some phages [31]. At that time, such an enzyme was only given a generic name, such as “lytic enzyme”, “lysin”, or even more often, “lysozyme” (as it will be later discussed). Specific names to distinguish true endolysins from these “structural lysins” probably only came into place when their widespread presence was experimentally established in the 1990s–2000s [32]. There is now an astonishing diversity of names for “structural lysins”. This latter term, for example, indicates that structural lysins are embedded within proteins that are a part of the virion structure and seem like a rather simple naming variation with little confusion risk at the moment. Other names emphasizing the structural character of these lysins are: “virion-associated peptidoglycan hydrolases” (VAPGHs or VAPHs, a disputable name on the basis of inaccurate description of the possible enzyme catalytic mechanism), “virion-associated lysins” (VALs), “tail-associated muralytic enzymes” (TAMEs) or “tail-associated lysins” (TALs). Another imaginative variant is “ectolysins”, which is indeed adequately derived as opposed to “endolysin”, emphasizing, in this case, that this kind of enzymes exerts lysis of the bacterial cell from without, although it is not widely adopted.

4. Names for Lysins as Antibacterial Agents

Once lysins were conceptualized as a new class of antibacterials in the context of the antibiotic resistance crisis, i.e., from the 2000s on, some new terms applied to lysins started to emerge. “Enzybiotics” is a name given to phage lysins purposed as antimicrobial agents. It is obviously a contraction of “enzyme-based antibiotics”, but the word misses the moiety “anti”, which has an essential meaning in “antibiotic” as “opposing life”. “Enzybiotic” is rather a term willing to indicate the use of enzymes as antibiotics by making up a similar word. This is to say, it would be a term applied to enzymes used to treat bacterial infections in a similar fashion as antibiotics. It was first coined by the V. Fischetti group [8], and since then it has been increasingly used, although “lysin” or “endolysin” seems to be much more popular still (Figure 1). While these latter terms are perfectly valid to refer to the enzymatic types of interest, the name “enzybiotic” indeed carries a more precise meaning as the molecule is explicitly applied as an antimicrobial. Therefore, not all lysins can be considered enzybiotics (or maybe they are all just potentially so) since not all lysins have been tested and purposed as antimicrobials. Also, the question of whether all enzybiotics can be considered lysins cannot be answered unequivocally. Since the main research on the repurposing of phage products as antimicrobials rely on lysins, the tendency is to implicitly equal “enzybiotic” to “lysin” [4]. Nonetheless, the term enzybiotic has also occasionally been applied to refer to the antimicrobial use of phage EPS depolymerases, and from a purely semantic perspective this seems correct to us given that depolymerases are enzymes and can be used in a similar fashion as antibiotics. Nevertheless, they act as antivirulence compounds rather than compounds that are directly bacteriostatic or bactericidal [52,53]. Some eccentric uses of this term are also documented, for example, the description of antimicrobial peptides (AMPs) as “membrane-targeted enzybiotics” [54], which would be, in our opinion, misleading, given the fact that AMPs are not, in principle, enzymes. Nevertheless, any other antimicrobial enzyme could be considered an enzybiotic, as has indeed already been pointed out [55]. This potentially includes phage lysins, bacterial lysins or autolysins (i.e., lysins produced by a bacterium to provoke its own lysis), phage or bacterial depolymerases, bacteriocins with an enzymatic action, or innate immunity lysozymes.
With the increasingly active research on lysin engineering to obtain better antimicrobial molecules, a plethora of names has been developed to distinguish between different engineering strategies. In fact, some efforts have already been made to provide a conceptual framework for the discussion of engineered lysins [56]. According to this framework, the first generation of lysins would be that of directly applied wild-type or natural lysins, while the second generation refers to lysins engineered to improve antibacterial and biochemical properties. There would be a third generation comprising those lysins engineered to enhance properties relevant under clinical conditions (bioavailability, half-life, interactions with the immune system, etc.). As a general term, synthetic lysin-based molecules are referred to as “engineered lysins”, regardless of whether they belong to the second or the third generation. Even more than mutagenesis, the development of novel engineered lysins relies on the principle of modular engineering, as explained in the previous section. This is how “chimeric lysins” (in a few cases also known as “chimeolysins”) started, first comprising only modules from peptidoglycan-degrading enzymes (both from phage and bacterial origin) and later incorporating functional modules from origins other than lysins too. An example of the latter are lysins fused to peptides able to permeabilize the outer membrane of Gram-negative bacterial cells and thus facilitate the antimicrobial activity of the peptidoglycan-degrading moiety. These are sometimes known as Artilysin®s, although this is a registered name by the company Lysando. Other engineering concepts focusing on outer membrane transfer have also been proposed, namely “innolysins” (a lysin fused to a phage receptor-binding protein or RBP [57] and lysocins (a lysin fused to a module from a bacteriocin) [58,59]. This latter name can be ambiguous since there is a new class of antibiotics that also go by the name of “lysocins” (Hamamoto, 2014).

5. Nomenclature of Individual Lysins

Another consequence of the newfound widespread interest in lysin research is the proliferation of different naming schemes used as common names for lysins. In the early stages of the molecular work on lysins, naming was rather functional and generally based on the original phage (e.g., T4 or T7 lysozyme, etc.). Further on, more “creative” names started to appear, mostly playing on the name and/or circumstances of the phage (e.g., Cpl-1 = “Complutense” phage lysin 1, being “complutense” the demonym of Alcalá de Henares, Spain, the place in which the original phage Cp-1 was isolated [60]). These non-standardized naming customs can still be found nowadays. But, more interestingly, efforts towards some standardization in naming schemes have also appeared. One of the most popular naming customs relies on the prefix “Lys”, referring to “lysin”, followed by the name of the phage, such as LysK (from Staphylococcus phage K [61]), LysGH15 (from Staphylococcus phage GH15 [62]), LysAB2 (from Acinetobacter phage phiAB2 [63]), and so on. An alternative is the prefix “Ply”, standing for “phage lysin”, normally also followed by the name of the phage itself (e.g., PlyC, PlySs2 [64,65]). The final traditional naming scheme for natural lysins would be that of using the name of the phage followed by the gene number, either preceded (OBPgp279, AP3gp15 [66,67]) or not (EL188, KZ144 [68]) by “gp”. These different traditions have become further complicated with the new engineering strategies. For engineered lysins there are, again, rather arbitrary names (such as Cpl-711, a chimeric lysin bearing the EAD of Cpl-7 and the linker and CBD from Cpl-1 [69]; or 1D10, which is the architectural variant at well D10 from screening plate 1 [70]) but also some standard ones. The prefix Cly is the counterpart of Ply for “chimeric lysins” (ClyS, ClyF, ClyJ [71,72,73]). Sometimes engineered lysins are the result of extracting domains from the original architecture, and this is noted in the names chosen, for example, for CHAPK (CHAP domain from LysK [74]) or LysRODIΔAmi (LysRODI lacking its central amidase domain [75]). Naming based on the domain family name has also been used for chimeric lysins (e.g., CHAPSH3 [76]). Other names are dependent on the specific engineering strategy applied, such as the Art-### scheme for Artilysin®s [77]. In any case, it would be a daunting task to thoroughly review the varied naming rationales for lysins, and this paragraph is only meant to serve as an example. So, it will suffice to conclude that the diversity in naming schemes for engineered lysins undoubtedly makes it difficult to keep up with the research being produced these days in the field, and the adoption of either standard names or “barcodes” for newly derived engineered lysins might be desirable. For example, it is nowadays hard to retrieve precise information about engineered lysins: it takes a lot of time to find all necessary information in the Materials and Methods section of a paper about the exact nucleotide/amino acid sequences, while data management and sharing have become increasingly important. Such barcoding practices could help to readily identify the origin and engineering rationale without having to actually dive into the text of every new piece of literature. Complementarily, it would be good practice to submit all sequences of newly derived engineered lysins to publicly available databases (NCBI, EMBL, etc.) and make use of initiatives such as PhaLP, which aggregates phage lysin data from the main public databases and may be a starting point towards standardization [15]. This, in turn, has the potential to steer new discoveries based on automated analysis coupled to further standardized experimental data.

6. Concluding Remarks

Science aims at using well-defined, standardized names to conceptualize and refer to the objects it works with. As such, specific names are a tool essential to the communicative and generalizable aspect of science: accurate names allow effective discussion to take place at the global scientific agora. This is a good enough reason for taking some time and effort reflect on how nomenclature is used within our very own research field and maybe even on how it can become more uniform in the near future. Phage research already has a very long tradition. As it has become clear throughout this review, the names used in the field of phage lysins have changed linked to the respective historical circumstances. From our point of view, there have been at least three waves that have caused naming diversification and/or confusion with definitions around phage lysins:
(1)
The first one exemplified by the liberal use of the term “lysin” at the early stages, applied in general to a still undescribed agent causing lysis and thus confusingly referring to what later would be defined as either true endolysins, structural lysins, phage depolymerases, or even the phage itself. The driver for confusion at this stage was not precisely knowing the nature of what was actually causing cell lysis (and, to a certain point, not even grasping the nature of the phage);
(2)
A second one driven by the initial lack of evidence or tools able to precisely define biochemical specificity, which at some point derived from the naming of lysins in general as “lysozymes”, a tradition that survived even after the name “lysozyme” was reserved for a precisely described catalytic mechanism of peptidoglycan hydrolysis;
(3)
A third one is our current era of engineered lysins, which is being driven by a variety of techniques or conceptualizations, and whose result is a remarkable diversification both in particular names for engineering strategies and naming schemes for individual lysins.
To these three, a fourth one may be added on top if we consider the names developed by companies devoted to phage lysin development for the purpose of market positioning. These range from general names for their lysin-based products (DLAs = “direct lytic agents”, EPLEs = “engineered phage lytic enzymes”) to new naming schemes for individual molecules (e.g., “Exebacase”, relying on the enzymatic suffix “-ase”, as recommended by the WHO for the International Nonproprietary Names [INNs] for enzymatic pharmaceuticals [78]).
At this point, we believe efforts toward correct name use and standardization should be welcomed to promote sharing and profit from the huge amount of data being produced around the world. For further clarity, a provisional glossary of phage lysin-related names discussed in this review can be found in Appendix A. As for naming standardization, some global initiatives already in place may be relevant to the topic, such as the enzymatic names and definitions by the International Union of Biochemistry and Molecular Biology (IUBMB, accessible here: https://www.enzyme-database.org (accessed on 5 August 2023)) or the ICTV position on the naming of phages [79], which could be used as an example to develop structured names for engineered lysins. To help initiate a fruitful discussion, a few key intervention points extracted from this article can be found in Appendix B. This may be a starting point for what we believe is an obligation of the whole lysin community towards achieving a widely supported nomenclature.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cells12152016/s1, a transcription and an English translation of the 1921 communication “Unicité du bacteriophage; Sur la lysine du bacteriophage” by F. D’Herelle and G. Eliava, Comptes Rendus de la Société de Biologie et de ses Filiales (85, 701–702).

Author Contributions

Conceptualization, R.V. and Y.B.; methodology, R.V.; investigation, R.V.; data curation, R.V.; writing—original draft preparation, R.V.; writing—review and editing, R.V. and Y.B.; visualization, R.V.; supervision, Y.B.; project administration, Y.B.; funding acquisition, Y.B. All authors have read and agreed to the published version of the manuscript.

Funding

R.V. was supported by a BOF postdoctoral fellowship (01P10022) awarded by Ghent University.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data was created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A. Glossary of Phage Lysin-Related Terms

NameProposed General DefinitionRemarks
ArtilysinRegistered name by the company Lysando describing specifically engineered lysins
Catalytic domain (CD)See “enzymatically active domain”
Cell wall-binding domain (CBD, CWBD)Domain of an enzyme whose main function is to bind to a cell wall component.
Cell wall-degrading enzymeSee “peptidoglycan-degrading enzyme”
ChimeolysinSee “chimeric lysin”
Chimeric endolysinSee “chimeric lysin”See remarks to “engineered endolysin”
Chimeric lysinEngineered lysin whose architecture is the result of fusing modules originating from different proteins
DLAA term introduced by the company ContraFect, describing antimicrobial agents that act by directly causing lysis of the bacterium.It may be used to refer to phage lysins or engineered lysins but also to lysin-causing antimicrobial peptides
DomainUnit of structural, functional and/or sequence conservation within a protein.
EctolysinSee “structural lysin”
EndolysinEnzyme encoded by a phage genome that causes bacterial cell lysis at the end of the phage lytic cycle, mainly by catalyzing peptidoglycan degradation, when released towards the cell wallShould be restricted only to natural phage lysins that exert their action from within the host cell
EndopeptidaseEnzyme that catalyzes the hydrolytic cleavage of peptide bonds, particularly not at the end of a peptide chain.General EC number for peptidases is 3.4. There are rather generalistic endopeptidases, such as l-alanoyl-d-glutamate endopeptidases, which cleave the peptide stem between two quite conserved amino acids and others that are more specific, such as some interpeptide bridge-specific endopeptidases (e.g., d-alanyl-glycyl endopeptidases, glycyl-glycyl endopeptidases, etc.)
Engineered endolysinEndolysin that has been modified with respect to its original, wild-type sequence(s)Conflicting name: since most engineered endolysins are not involved by principle in bacterial lysis from within the cell, “engineered lysin” would be a more etymologically correct term. Only in some specific circumstances “engineered endolysin” may be more accurate.
Engineered lysinLysin that has been modified with respect to its original, wild-type sequence(s)
EnzybioticEnzyme that works as an antimicrobial agent
Enzymatically active domain (EAD)Domain of an enzyme whose main function is to catalyze a reaction
EPLEEngineered phage lytic enzyme, see “engineered lysin”. A name introduced by the company Telum Therapeutics.
GlucosaminidaseEnzyme that catalyzes hydrolysis of terminal non-reducing N-acetyl-d-hexosamine residues. Particularly, among lysins, glucosaminidases break the bond between N-acetyl-d-glucosamine and N-acetyl muramic acid at the reducing side of the formerEC 3.2.1.52, accepted name: β-N-acetylhexosaminidase, full name: N-acetyl-β-d-glucosaminidase
HolinProtein encoded by a phage genome that forms large pores at the inner membrane of the bacterial host to release endolysins to the cell wall at the end of the phage lytic cycle
InnolysinChimeric lysin that is made up of modules originating from a lysin plus a phage receptor-binding protein (RBP)
LysinEnzyme that catalytically degrades the cell wall peptidoglycan. Broad term, could be applied to phage lysins, bacterial lysins, engineered ones, etc.
Lysin AEnzyme encoded at the genome of a phage infecting diderm bacteria with an arabino-mycolyl outer layer that exerts bacterial host cell lysis by cleaving peptidoglycan bondsMay be just named “endolysin”
Lysin BEnzyme encoded at the genome of a phage infecting diderm bacteria with an arabino-mycolyl outer layer that exerts bacterial host cell lysis by cleaving arabino-mycolyl ester bonds
LysocinChimeric lysin that is made up of modules originating from a lysin and bacteriocin elements responsible for surface receptor-binding and outer membrane translocationConflicting name: a class of antibiotics is already called “lysocins”
LysozymeEnzyme that hydrolytically cleaves the 1,4-β-linkages between N-acetylmuramic acid and N-acetyl-d-glucosamine residues in peptidoglycan (and between two N-acetyl-d-glucosamine residues in chitodextrins)EC 3.2.1.17
Lytic transglycosylaseEnzyme that catalyzes non-hydrolytic cleavage of the bond between N-acetyl-d-glucosamine and N-acetyl muramic acid through a process in which a sugar molecule is transformed into another (an anhydro derivative)EC 4.2.2.n (still not definitive EC number). Alternative name: muropeptide lyase
ModuleStructural and functional element from a protein (or other composite entity) that is interchangeable or susceptible to be integrated into another higher-order unit
MuralysinSee “peptidoglycan-degrading enzyme”
Muralytic enzymeSee “peptidoglycan-degrading enzyme”
MuramidaseSee “lysozyme”Full name: 1,4-β-N-acetylmuramidase
Murein hydrolaseSee “peptidoglycan hydrolase”
N-acetylmuramoyl (NAM-)amidaseEnzyme that catalyzes hydrolytic cleavage of the bond between N-acetylmuramoyl and an l-amino acid residue of the stem peptide of the peptidoglycanEC 3.5.1.28, full name: N-acetylmuramoyl-l-alanine amidase
OMP“Outer membrane permeabilizing”, typically a peptide able to interact and permeabilize biological membranes and, in particular, the outer membrane of Gram-negative bacteria
PeptidaseSee “endopeptidase”The lack of the prefix “endo-” implies that the site of cleavage (terminus or internal site) is not specified. IUBMB does not recommend the term “peptidase”, thus “endopeptidase” is preferred in the context of phage lysins
Peptidoglycan hydrolase (PGH)Enzyme that catalyzes the hydrolytic cleavage of bonds within the peptidoglycanNot equivalent to “peptidoglycan-degrading enzyme” since there are peptidoglycan lyases (e.g., lytic transglycosylases)
Peptidoglycan-degrading enzymeEnzyme that catalyzes the cleavage of bonds within the peptidoglycanNot restricted to phage lysins, e.g., peptidoglycan recycling/remodeling enzymes or autolysins from bacterial origin are peptidoglycan-degrading enzymes as well
Phage depolymeraseProtein encoded by a phage genome that catalyzes the cleavage of bonds within the exopolysaccharides produced by some bacterial hosts thus facilitating subsequent infection by the virion particlesNot fully distinguished from phage lysins in very early literature
(Phage) exopolysaccharide depolymeraseSee “phage depolymerase”
Phage lysinEnzyme encoded by a phage genome that catalytically degrades the cell wall peptidoglycanDenoting phage origin should be preferred to avoid ambiguities (thus “phage lysin” should be preferred over just “lysin” when referring to lysins from phages)
Phage lytic enzymeSee “phage lysin”
Phage lytic proteinProtein encoded by a phage genome that catalytically degrades the cell wall peptidoglycan or that noncatalytically exerts bacterial cell lysisCan potentially be applied both to (endo)lysins, structural lysins -both enzymes- and the rest of nonenzymatic lysis actors (holins, spanins…)
PinholinProtein encoded by a phage genome that forms small pores at the inner membrane of the bacterial host cell to allow the activation of signal-arrest-release (SAR-)endolysins
ReleasinProtein encoded by a phage genome that allows release and activation of a SAR-endolysin by a mechanism other than that of pinholins
SpaninProtein encoded at the genome of a phage infecting diderm, Gram-negative bacteria whose function is to span the periplasm allowing the physical contact of inner and outer membrane to form large pores and then produce the efficient lysis of the bacterial cell host at the end of the lytic cycle
Structural lysinEnzyme encoded by a phage genome that catalyzes the cleavage of peptidoglycan and is present within the virion particle
Tail-associated lysin (TAL)See “structural lysin”
Tail-associated muralytic enzyme (TAME)See “structural lysin”
Virion-associated lysinSee “structural lysin”
Virion-associated peptidoglycan hydrolase (VAPGH, VAPH)Enzyme encoded by a phage genome that catalyzes the hydrolytic cleavage of peptidoglycan bonds and is present within the virion particleDoes not include all structural lysins (since some of them are potentially lyases and not hydrolases)

Appendix B

The following is a short list of key points towards nomenclature standardization in the phage lysin field:
(1)
General names (lysin, endolysin, enzybiotic, etc.) should be used, taking into account their actual meaning in the biological context or their actual application;
(2)
Names referring to catalytic activities should be used with care, restricting them to those cases in which confirmatory empirical evidence exists. Alternatively, the adjectives “predicted” or “putative” should be added. This also applies to the general term “hydrolase”, which, stricto sensu, does not include many phage lysins that are lyases;
(3)
While the interchangeable use of “domain” and “module” in the phage lysin field may be acceptable, we suggest that some attention is paid to the suitability of the semantic nuances of each term. Therefore, “domain” may be preferably used to describe structural/functional features of the proteins, whereas “module” serves more to discussions about the combinatorial nature of phage lysins from evolution or engineering perspectives;
(4)
The field could benefit from an agreement on a preferred naming scheme for individual phage lysins, such as the “Ply” or “Lys” nomenclatures. From our point of view, the “Ply” scheme has the additional benefit of the versatility to explicitly name different realities within the phage lysin realm, e.g.,: Ply = phage lysins in general or rather endolysins, Cly = chimeric lysins. One can think of variants for structural lysins such as Sly (“structural lysin”) or Vly (“virion-associated lysin”) or, in general, for engineered lysins (e.g., Ely);
(5)
An additional effort in precisely describing engineered lysins in the literature is due, perhaps adopting some sort of in-text “barcode” elaborating how the engineered lysin is derived from its parental sequences with exact amino acid positions, plus transparently using public databases for engineered lysins as well.

References

  1. Gordillo Altamirano, F.L.; Barr, J.J. Phage Therapy in the Postantibiotic Era. Clin. Microbiol. Rev. 2019, 32, 10–1128. [Google Scholar] [CrossRef] [PubMed]
  2. Vázquez, R.; Diez-Martínez, R.; Domingo-Calap, P.; García, P.; Gutiérrez, D.; Muniesa, M.; Ruiz-Ruigómez, M.; Sanjuán, R.; Tomás, M.; Tormo-Mas, M.A.; et al. Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain. Microorganisms 2022, 10, 717. [Google Scholar] [CrossRef] [PubMed]
  3. Nelson, D.C.; Schmelcher, M.; Rodriguez-Rubio, L.; Klumpp, J.; Pritchard, D.G.; Dong, S.; Donovan, D.M. Endolysins as Antimicrobials. Adv. Virus Res. 2012, 83, 299–365. [Google Scholar] [CrossRef] [PubMed]
  4. Dams, D.; Briers, Y. Enzybiotics: Enzyme-Based Antibacterials as Therapeutics. Adv. Exp. Med. Biol. 2019, 1148, 233–253. [Google Scholar] [CrossRef]
  5. Vázquez, R.; García, E.; García, P. Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials. Front. Immunol. 2018, 9, 2252. [Google Scholar] [CrossRef]
  6. Fischetti, V.A. Development of Phage Lysins as Novel Therapeutics: A Historical Perspective. Viruses 2018, 10, 310. [Google Scholar] [CrossRef]
  7. Loeffler, J.M.; Nelson, D.; Fischetti, V.A. Rapid Killing of Streptococcus pneumoniae with a Bacteriophage Cell Wall Hydrolase. Science 2001, 294, 2170–2172. [Google Scholar] [CrossRef] [PubMed]
  8. Nelson, D.; Loomis, L.; Fischetti, V.A. Prevention and Elimination of Upper Respiratory Colonization of Mice by Group A Streptococci by Using a Bacteriophage Lytic Enzyme. Proc. Natl. Acad. Sci. USA 2001, 98, 4107–4112. [Google Scholar] [CrossRef]
  9. Avery, O.T.; Dubos, R. The Protective Action of a Specific Enzyme against Type Iii Pneumococcus Infection in Mice. J. Exp. Med. 1931, 54, 73–89. [Google Scholar] [CrossRef]
  10. Fleming, A. On a Remarkable Bacteriolytic Element Found in Tissues and Secretions. Proc. R Soc. B: Biol Sci 1922, 93, 306–317. [Google Scholar]
  11. Gerstmans, H.; Criel, B.; Briers, Y. Synthetic Biology of Modular Endolysins. Biotechnol. Adv. 2018, 36, 624–640. [Google Scholar] [CrossRef]
  12. Oechslin, F.; Menzi, C.; Moreillon, P.; Resch, G. The Multi-Domain Architecture of a Bacteriophage Endolysin Enables Intramolecular Synergism and Regulation of Bacterial Lysis. J. Biol. Chem. 2021, 296, 100639. [Google Scholar] [CrossRef] [PubMed]
  13. Randich, A.M.; Kysela, D.T.; Morlot, C.; Brun, Y.V. Origin of a Core Bacterial Gene via Co-Option and Detoxification of a Phage Lysin. Curr. Biol. 2019, 29, 1634–1646 e6. [Google Scholar] [CrossRef]
  14. Vázquez, R.; Seoane-Blanco, M.; Rivero-Buceta, V.; Ruiz, S.; van Raaij, M.J.; García, P. Monomodular Pseudomonas Aeruginosa Phage JG004 Lysozyme (Pae87) Contains a Bacterial Surface-Active Antimicrobial Peptide-like Region and a Possible Substrate-Binding Subdomain. Acta Crystallogr. D. Struct. Biol. 2022, 78, 435–454. [Google Scholar] [CrossRef] [PubMed]
  15. Criel, B.; Taelman, S.; Van Criekinge, W.; Stock, M.; Briers, Y. PhaLP: A Database for the Study of Phage Lytic Proteins and Their Evolution. Viruses 2021, 13, 1240. [Google Scholar] [CrossRef] [PubMed]
  16. Oliveira, H.; Melo, L.D.; Santos, S.B.; Nobrega, F.L.; Ferreira, E.C.; Cerca, N.; Azeredo, J.; Kluskens, L.D. Molecular Aspects and Comparative Genomics of Bacteriophage Endolysins. J. Virol. 2013, 87, 4558–4570. [Google Scholar] [CrossRef] [PubMed]
  17. Vázquez, R.; García, E.; García, P. Sequence-Function Relationships in Phage-Encoded Bacterial Cell Wall Lytic Enzymes and Their Implications for Phage-Derived Products Design. J. Virol. 2021, 95, 10–1128. [Google Scholar] [CrossRef]
  18. Abdelkader, K.; Gerstmans, H.; Saafan, A.; Dishisha, T.; Briers, Y. The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts Are Easier than the Whole. Viruses 2019, 11, 96. [Google Scholar] [CrossRef]
  19. World Health Organization. Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis; World Health Organization: Geneva, Switzerland, 2021. [Google Scholar]
  20. D’Herelle, F.; Eliava, G. Unicité Du Bactériophage; Sur La Lysine Du Bactériophage. Comp. Rend. Soc. Biol. 1921, 85, 701–702. [Google Scholar]
  21. Twort, F. The Transmissible Bacterial Lysin and Its Action on Dead Bacteria. Lancet 1925, 206, 642–644. [Google Scholar] [CrossRef]
  22. Delbrück, M. Bacterial Viruses (Bacteriophages). Adv. Enzymol. Relat. Subj. Biochem. 1942, 2, 1–32. [Google Scholar]
  23. Adhya, S.L.; Sen, A.; Mitra, S. The Role of Gene, S. Cold Spring Harb. Monog. Arch. 1971, 02, 743–746. [Google Scholar]
  24. Young, R. Phage Lysis: Three Steps, Three Choices, One Outcome. J. Microbiol. 2014, 52, 243–258. [Google Scholar] [CrossRef] [PubMed]
  25. Chamblee, J.S.; Ramsey, J.; Chen, Y.; Maddox, L.T.; Ross, C.; To, K.H.; Cahill, J.L.; Young, R. Endolysin Regulation in Phage Mu Lysis. mBio 2022, 13, e0081322. [Google Scholar] [CrossRef] [PubMed]
  26. Akira Tsugita Phage Lysozyme and Other Lytic Enzymes. Enzymes 1971, 5, 343–411. [CrossRef]
  27. Jacob, F.; Fuerst, C.R.; Wollman, E.L. Study of Defective Lysogenic Bacteria. II.-Physiological Types resulting from Prophage Mutations. Ann. Inst. Pasteur 1957, 93, 724–753. [Google Scholar]
  28. Campbell, A. Sensitive Mutants of Bacteriophage λ. Virology 1961, 14, 22–32. [Google Scholar] [CrossRef]
  29. Groman, N.B.; Suzuki, G. Relation of Endolysin to Lysis by Lambda Bacteriophages. J. Bacteriol. 1962, 84, 596–597. [Google Scholar] [CrossRef] [PubMed]
  30. London, J.; Appleman, M.D. Oxidative and Glycerol Metabolism of Two Species of Enterococci. J. Bacteriol. 1962, 84, 597–598. [Google Scholar] [CrossRef]
  31. Barrington, L.F.; Kozloff, L.M. Action of Bacteriophage on Isolated Host Cell Walls. J Biol. Chem. 1956, 223, 615–627. [Google Scholar] [CrossRef]
  32. Moak, M.; Molineux, I.J. Peptidoglycan Hydrolytic Activities Associated with Bacteriophage Virions. Mol. Microbiol. 2004, 51, 1169–1183. [Google Scholar] [CrossRef] [PubMed]
  33. Ruska, H. Über Ein Neues Bei Der Bakteriophagen Lyse Auftretendes Formelement. Naturwissenschaften 1941, 29, 367–368. [Google Scholar] [CrossRef]
  34. Luria, S.E.; Delbruck, M.; Anderson, T.F. Electron Microscope Studies of Bacterial Viruses. J. Bacteriol. 1943, 46, 57–77. [Google Scholar] [CrossRef]
  35. Salton, M.R. The Properties of Lysozyme and Its Action on Microorganisms. Bacteriol. Rev. 1957, 21, 82–100. [Google Scholar] [CrossRef]
  36. Koch, G.; Dreyer, W.J. Characterization of an Enzyme of Phage T2 as a Lysozyme. Virology 1958, 6, 291–293. [Google Scholar] [CrossRef] [PubMed]
  37. Garcia, E. On the Misuse of the Term “Lysozyme”. Mol. Microbiol. 1996, 21, 885. [Google Scholar] [CrossRef] [PubMed]
  38. Herrlich, P.; Schweiger, M. T3 and T7 Bacteriophage Deoxyribonucleic Acid-Directed Enzyme Synthesis in Vitro. J. Virol. 1970, 6, 750–753. [Google Scholar] [CrossRef]
  39. Inouye, M.; Arnheim, N.; Sternglanz, R. Bacteriophage T7 Lysozyme Is an N-Acetylmuramyl-l-Alanine Amidase. J. Biol. Chem. 1973, 248, 7247–7252. [Google Scholar] [CrossRef]
  40. Taylor, A.; Das, B.C.; Van Heijenoort, J. Bacterial-Cell-Wall Peptidoglycan Fragments Produced by Phage λ or Vi II Endolysin and Containing 1,6-Anhydro-N-Acetylmuramic Acid. European J. Biochem. 1975, 53, 47–54. [Google Scholar] [CrossRef]
  41. Bieʼnkowska-Szewczyk, K.; Lipiʼnska, B.; Taylor, A. The R Gene Product of Bacteriophage λ Is the Murein Transglycosylase. Molec. Gen. Genet. 1981, 184, 111–114. [Google Scholar] [CrossRef]
  42. Kravchenko, N.A.; Perutz, M.F. Lysozyme as a Transferase. Proc. R. Soc. B: Biol. Sci. 1997, 167, 429–430. [Google Scholar] [CrossRef]
  43. Kawamura, S.; Eto, M.; Imoto, T.; Ikemizu, S.; Araki, T.; Torikata, T. Functional and Structural Effects of Mutagenic Replacement of Asn37 at Subsite F on the Lysozyme-Catalyzed Reaction. Biosci. Biotechnol. Biochem. 2004, 68, 593–601. [Google Scholar] [CrossRef] [PubMed][Green Version]
  44. Kuroki, R.; Weaver, L.H.; Matthews, B.W. Structural Basis of the Conversion of T4 Lysozyme into a Transglycosidase by Reengineering the Active Site. PNAS 1999, 96, 8949–8954. [Google Scholar] [CrossRef]
  45. Botstein, D.; Herskowitz, I. Properties of Hybrids between Salmonella Phage P22 and Coliphage λ. Nature 1974, 251, 584–589. [Google Scholar] [CrossRef]
  46. Botstein, D. A Theory of Modular Evolution for Bacteriophages. Ann. N. Y. Acad. Sci. 1980, 354, 484–490. [Google Scholar] [CrossRef] [PubMed]
  47. Garcia, E.; Garcia, J.L.; Garcia, P.; Arraras, A.; Sanchez-Puelles, J.M.; Lopez, R. Molecular Evolution of Lytic Enzymes of Streptococcus Pneumoniae and Its Bacteriophages. Proc. Natl. Acad. Sci. USA 1988, 85, 914–918. [Google Scholar] [CrossRef] [PubMed]
  48. García, P.; García, J.L.; García, E.; Sánchez-Puelles, J.M.; López, R. Modular Organization of the Lytic Enzymes of Streptococcus Pneumoniae and Its Bacteriophages. Gene 1990, 86, 81–88. [Google Scholar] [CrossRef]
  49. Diaz, E.; Lopez, R.; Garcia, J.L. Chimeric Pneumococcal Cell Wall Lytic Enzymes Reveal Important Physiological and Evolutionary Traits. J. Biol. Chem. 1991, 266, 5464–5471. [Google Scholar] [CrossRef]
  50. Schaeffer, R.D.; Daggett, V. Protein Folds and Protein Folding. PEDS 2011, 24, 11–19. [Google Scholar] [CrossRef]
  51. Guillén, D.; Sánchez, S.; Rodríguez-Sanoja, R. Carbohydrate-Binding Domains: Multiplicity of Biological Roles. Appl. Microbiol. Biotechnol. 2010, 85, 1241–1249. [Google Scholar] [CrossRef]
  52. Drulis-Kawa, Z.; Majkowska-Skrobek, G.; Maciejewska, B.; Delattre, A.-S.; Lavigne, R. Learning from Bacteriophages-Advantages and Limitations of Phage and Phage-Encoded Protein Applications. Curr. Protein Pept. Sci. 2012, 13, 699–722. [Google Scholar] [CrossRef]
  53. Majkowska-Skrobek, G.; Latka, A.; Berisio, R.; Squeglia, F.; Maciejewska, B.; Briers, Y.; Drulis-Kawa, Z. Phage-Borne Depolymerases Decrease Klebsiella Pneumoniae Resistance to Innate Defense Mechanisms. Front. Microbiol. 2018, 9, 2517. [Google Scholar] [CrossRef]
  54. Gasset, M. Membrane-Targeted Enzybiotics. In Enzybiotics; John Wiley & Sons, Ltd.: New York, NY, USA, 2009; pp. 173–198. ISBN 978-0-470-57054-8. [Google Scholar]
  55. 5Danis-Wlodarczyk, K.M.; Wozniak, D.J.; Abedon, S.T. Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application. Antibiotics 2021, 10, 1497. [Google Scholar] [CrossRef]
  56. De Maesschalck, V.; Gutierrez, D.; Paeshuyse, J.; Lavigne, R.; Briers, Y. Advanced Engineering of Third-Generation Lysins and Formulation Strategies for Clinical Applications. Crit. Rev. Microbiol. 2020, 46, 548–564. [Google Scholar] [CrossRef]
  57. Zampara, A.; Sorensen, M.C.H.; Grimon, D.; Antenucci, F.; Vitt, A.R.; Bortolaia, V.; Briers, Y.; Brondsted, L. Exploiting Phage Receptor Binding Proteins to Enable Endolysins to Kill Gram-Negative Bacteria. Sci. Rep. 2020, 10, 12087. [Google Scholar] [CrossRef] [PubMed]
  58. Heselpoth, R.D.; Euler, C.W.; Schuch, R.; Fischetti, V.A. Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria. Antimicrob. Agents Chemother. 2019, 63, e00342-19. [Google Scholar] [CrossRef]
  59. Lukacik, P.; Barnard, T.J.; Buchanan, S.K. Using a Bacteriocin Structure to Engineer a Phage Lysin That Targets Yersinia Pestis. Biochem. Soc. Trans. 2012, 40, 1503–1506. [Google Scholar] [CrossRef] [PubMed]
  60. Ronda, C.; López, R.; García, E. Isolation and Characterization of a New Bacteriophage, Cp-1, Infecting Streptococcus Pneumoniae. J. Virol. 1981, 40, 551–559. [Google Scholar] [CrossRef]
  61. O’Flaherty, S.; Coffey, A.; Meaney, W.; Fitzgerald, G.F.; Ross, R.P. The Recombinant Phage Lysin LysK Has a Broad Spectrum of Lytic Activity against Clinically Relevant Staphylococci, Including Methicillin-Resistant Staphylococcus Aureus. J. Bacteriol. 2005, 187, 7161–7164. [Google Scholar] [CrossRef] [PubMed]
  62. Gu, J.; Xu, W.; Lei, L.; Huang, J.; Feng, X.; Sun, C.; Du, C.; Zuo, J.; Li, Y.; Du, T.; et al. LysGH15, a Novel Bacteriophage Lysin, Protects a Murine Bacteremia Model Efficiently against Lethal Methicillin-Resistant Staphylococcus Aureus Infection. J. Clin. Microbiol. 2011, 49, 111–117. [Google Scholar] [CrossRef]
  63. Lai, M.J.; Lin, N.T.; Hu, A.; Soo, P.C.; Chen, L.K.; Chen, L.H.; Chang, K.C. Antibacterial Activity of Acinetobacter Baumannii Phage VarphiAB2 Endolysin (LysAB2) against Both Gram-Positive and Gram-Negative Bacteria. Appl. Microbiol. Biotechnol. 2011, 90, 529–539. [Google Scholar] [CrossRef]
  64. Nelson, D.; Schuch, R.; Chahales, P.; Zhu, S.; Fischetti, V.A. PlyC: A Multimeric Bacteriophage Lysin. Proc. Natl. Acad. Sci. USA 2006, 103, 10765–10770. [Google Scholar] [CrossRef] [PubMed]
  65. Gilmer, D.B.; Schmitz, J.E.; Euler, C.W.; Fischetti, V.A. Novel Bacteriophage Lysin with Broad Lytic Activity Protects against Mixed Infection by Streptococcus Pyogenes and Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2013, 57, 2743–2750. [Google Scholar] [CrossRef] [PubMed]
  66. Walmagh, M.; Briers, Y.; dos Santos, S.B.; Azeredo, J.; Lavigne, R. Characterization of Modular Bacteriophage Endolysins from Myoviridae Phages OBP, 201phi2-1 and PVP-SE1. PLoS ONE 2012, 7, e36991. [Google Scholar] [CrossRef] [PubMed]
  67. Maciejewska, B.; Zrubek, K.; Espaillat, A.; Wisniewska, M.; Rembacz, K.P.; Cava, F.; Dubin, G.; Drulis-Kawa, Z. Modular Endolysin of Burkholderia AP3 Phage Has the Largest Lysozyme-like Catalytic Subunit Discovered to Date and No Catalytic Aspartate Residue. Sci. Rep. 2017, 7, 14501. [Google Scholar] [CrossRef] [PubMed]
  68. Briers, Y.; Volckaert, G.; Cornelissen, A.; Lagaert, S.; Michiels, C.W.; Hertveldt, K.; Lavigne, R. Muralytic Activity and Modular Structure of the Endolysins of Pseudomonas aeruginosa Bacteriophages PhiKZ and EL. Mol. Microbiol. 2007, 65, 1334–1344. [Google Scholar] [CrossRef]
  69. Diez-Martinez, R.; De Paz, H.D.; Garcia-Fernandez, E.; Bustamante, N.; Euler, C.W.; Fischetti, V.A.; Menendez, M.; Garcia, P. A Novel Chimeric Phage Lysin with High in Vitro and in Vivo Bactericidal Activity against Streptococcus Pneumoniae. J. Antimicrob. Chemother. 2015, 70, 1763–1773. [Google Scholar] [CrossRef] [PubMed]
  70. Gerstmans, H.; Grimon, D.; Gutierrez, D.; Lood, C.; Rodriguez, A.; van Noort, V.; Lammertyn, J.; Lavigne, R.; Briers, Y. A VersaTile-Driven Platform for Rapid Hit-to-Lead Development of Engineered Lysins. Sci. Adv. 2020, 6, eaaz1136. [Google Scholar] [CrossRef] [PubMed]
  71. Daniel, A.; Euler, C.; Collin, M.; Chahales, P.; Gorelick, K.J.; Fischetti, V.A. Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus Aureus. Antimicrob. Agents Chemother. 2010, 54, 1603–1612. [Google Scholar] [CrossRef]
  72. Yang, H.; Zhang, H.; Wang, J.; Yu, J.; Wei, H. A Novel Chimeric Lysin with Robust Antibacterial Activity against Planktonic and Biofilm Methicillin-Resistant Staphylococcus aureus. Sci. Rep. 2017, 7, 40182. [Google Scholar] [CrossRef]
  73. Yang, H.; Gong, Y.; Zhang, H.; Etobayeva, I.; Miernikiewicz, P.; Luo, D.; Li, X.; Zhang, X.; Dąbrowska, K.; Nelson, D.C.; et al. ClyJ Is a Novel Pneumococcal Chimeric Lysin with a Cysteine- and Histidine-Dependent Amidohydrolase/Peptidase Catalytic Domain. Antimicrob. Agents Chemother. 2019, 63, e02043-18. [Google Scholar] [CrossRef]
  74. Fenton, M.; Casey, P.G.; Hill, C.; Gahan, C.G.; Ross, R.P.; McAuliffe, O.; O’Mahony, J.; Maher, F.; Coffey, A. The Truncated Phage Lysin CHAPK Eliminates Staphylococcus aureus in the Nares of Mice. Bioeng. Bugs. 2010, 1, 404–407. [Google Scholar] [CrossRef] [PubMed]
  75. Gutiérrez, D.; Rodríguez-Rubio, L.; Ruas-Madiedo, P.; Fernández, L.; Campelo, A.B.; Briers, Y.; Nielsen, M.W.; Pedersen, K.; Lavigne, R.; García, P.; et al. Design and Selection of Engineered Lytic Proteins With Staphylococcus Aureus Decolonizing Activity. Front. Microbiol. 2021, 12, 723834. [Google Scholar] [CrossRef] [PubMed]
  76. Rodríguez-Rubio, L.; Martínez, B.; Rodríguez, A.; Donovan, D.M.; García, P. Enhanced Staphylolytic Activity of the Staphylococcus Aureus Bacteriophage VB_SauS-PhiIPLA88 HydH5 Virion-Associated Peptidoglycan Hydrolase: Fusions, Deletions, and Synergy with LysH5. Appl. Environ. Microbiol. 2012, 78, 2241–2248. [Google Scholar] [CrossRef] [PubMed]
  77. Briers, Y.; Walmagh, M.; Grymonprez, B.; Biebl, M.; Pirnay, J.P.; Defraine, V.; Michiels, J.; Cenens, W.; Aertsen, A.; Miller, S.; et al. Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas Aeruginosa. Antimicrob. Agents Chemother. 2014, 58, 3774–3784. [Google Scholar] [CrossRef] [PubMed]
  78. World Health Organization. Guidance on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances; World Health Organization: Geneva, Switzerland, 2017. [Google Scholar]
  79. Kropinski, A.M.; Prangishvili, D.; Lavigne, R. Position Paper: The Creation of a Rational Scheme for the Nomenclature of Viruses of Bacteria and Archaea. Environ. Microbiol. 2009, 11, 2775–2777. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
Hesperidin Ameliorates Sarcopenia through the Regulation of Inflammaging and the AKT/mTOR/FoxO3a Signaling Pathway in 22–26-Month-Old Mice
Previous
The Role of Swelling in the Regulation of OPA1-Mediated Mitochondrial Function in the Heart In Vitro
Next